Lepu Medical
Engaged in the R&D, production and sales of cardiovascular disease plant intervention diagnosis and treatment equipment and cardiovascular drugs.
Lepu Medical, founded in June, 1999 and headquartered in Beijing, is an enterprise engaged in the R&D, production and sales of cardiovascular drugs and cardiovascular disease plant interventional diagnosis and treatment equipment . The founder is Pu Zhongjie. Listed on the SZSE on October 30, 2009, the company's major shareholders are Luoyang Ship Material Research Institute, Pu Zhongjie and WP Medical Technologies, INC. Rivals that have direct and indirect competition with Lepu Medical include Peijia, Kintor, Aprea Therapeutics, Viela, etc.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery
The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.
Mar 30, 2023 04:00 PM
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
Medical Equipment Company PowerSite Nets Over CNY 100 Mn in Series B
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
Artificial Cardiac Company CoretechMed Raises Nearly CNY 200 Mn in Series C+
In the past five years, China's ventricular assist technology (i.e., "artificial heart") has developed rapidly, and three domestic implantable ventricular assist devices (LVADs) have been approved and marketed by the State Drug Administration, and another one is in the marketing declaration stage. The number of LVAD implantations has increased yearly, with a total of 363 LVAD implantations performed in 70 hospitals, a rapid increase.
Apr 17, 2023 05:12 PM
Equipment Company Keyto Nets Over CNY 100 Mn in Series C
State Affairs Office: revise and issue the negative list of market access (2021 version) before the end of the year to carry out the pilot of relaxing market access